Get the Stockscreener App
53.57
3.60%
1.86
After Hours:
53.68
0.11
+0.21%
Moderna Inc stock is traded at $53.57, with a volume of 9.04M.
It is up +3.60% in the last 24 hours and up +17.87% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$51.71
Open:
$51.27
24h Volume:
9.04M
Relative Volume:
0.79
Market Cap:
$20.93B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-6.1363
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+7.42%
1M Performance:
+17.87%
6M Performance:
+113.43%
1Y Performance:
+72.31%
1-Day Range:
$50.73
$53.62
1-Week Range:
$48.68
$54.02
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
53.57 | 20.20B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating - marketscreener.com
Uncertainty Looms Over Pharma’s Legal Strategy as States Challenge New Vaccine Schedule - BioSpace
Moderna (MRNA) Gains EMA Recommendation for Combo Vaccine - GuruFocus
Why Is Moderna Stock Moving Today? Europe Clears Moderna’s Dual Vaccine - Tokenist
EU regulator backs approval for Moderna’s combined COVID, flu shot - WTVB
EU regulator backs approval for Moderna's combined COVID and flu vaccine - marketscreener.com
Moderna Gets EU Approval for mRNA Combination Covid-Flu Shot - Bloomberg.com
Moderna’s flu-COVID combo vaccine gets EU regulatory backing By Investing.com - Investing.com India
Moderna Says It Received Positive EU Panel Opinion for Flu-COVID Combination Vaccine - marketscreener.com
Moderna (MRNA) Gains Positive Opinion for Combo Vaccine in EU - GuruFocus
Moderna (MRNA) Nears EU Approval for Combined Flu and COVID-19 V - GuruFocus
Moderna’s Covid-Flu Vaccine Recommended for Approval in EU - WSJ
World’s first flu-COVID combo shot wins key EU backing for over-50s - Stock Titan
Moderna’s combination flu, COVID shot wins over European drug regulators - Yahoo Finance
Moderna Wins European Medicines Agency's Positive Opinion for Combined COVID-19, Influenza Vaccine - marketscreener.com
Ema recommends granting marketing authorisation in EU for mCombriax - marketscreener.com
Moderna (MRNA) Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine - simplywall.st
Moderna (MRNA) Stock Review: Performance & Valuation Concerns in 2026News and Statistics - IndexBox
Moderna president Hoge sells $7.8m in MRNA stock - Investing.com South Africa
Moderna president Hoge sells $7.8m in MRNA stock By Investing.com - Investing.com Canada
Stephen Hoge Sells 160,009 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna Royalty Opinion Loss Raises Covid-Shot Trial Stakes (1) - Bloomberg Law News
Moderna's Damages Expert Limited In March Patent Trial - Law360
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - Nasdaq
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - The Motley Fool
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Finviz
A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound - Yahoo Finance Singapore
MRNA Stock Surges 26% With A 7-day Winning Spree On FDA Flu Vaccine Review - Trefis
How To Read FDA's Flip-Flop On Moderna Flu Vaccine - Law360
What the Options Market Tells Us About ModernaModerna (NASDAQ:MRNA) - Benzinga
Moderna says FDA will consider its new flu shot after resolving public dispute - Devils Lake Journal
Moderna Stock: How Far Can The Flu Shot Fly? - Forbes
Will the FDA yank mRNA vaccines? - PharmaVoice
Moderna Shares Surge on Stronger-Than-Expected Revenue and Strategic Pivot - AD HOC NEWS
MRNA Stock Surges 25% With A 6-day Winning Spree On FDA Flu Shot Review - Trefis
Gilead’s Arcellx buy. Plus: ctDNA as surrogate endpoint — a BioCentury podcast - biocentury.com
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost - marketscreener.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating a -15.68% Potential Downside Amid Revenue Challenges - DirectorsTalk Interviews
Moderna Faces New Challenges and Opportunities Ahead - Intellectia AI
Moderna’s Stock Surges Amid New Agreements and Regulatory Approvals - StocksToTrade
Piper Sandler raises Moderna stock price target on vaccine pipeline By Investing.com - Investing.com India
Piper Sandler raises Moderna stock price target on vaccine pipeline - Investing.com
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear - Yahoo Finance
Piper Sandler Revises Price Target for MRNA, Maintains 'Overweig - GuruFocus
Scientists identify new spinosaurid, Moderna flu shot back on track, universal inhaled vaccine shows promise - Scientific American
Aberdeen Group plc Reduces Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission - ACCESS Newswire
Moderna (MRNA) Leads Healthcare Gains with 24.33% Surge - GuruFocus
500,000 Shares in Moderna, Inc. $MRNA Bought by Telemark Asset Management LLC - MarketBeat
Vanguard Group Inc. Has $1.06 Billion Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Faces Default Risk as Ares Capital–Led Lenders Gain Power to Accelerate Debt and Seize Collateral - TipRanks
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Feb 23 '26 |
Sale |
48.84 |
160,009 |
7,814,840 |
1,457,427 |
1.58%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):